Clinical Trial Update: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of 64Cu-SAR-bisPSMA for identifying recurrence of prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-SAR-bisPSMA (Copper-64-labeled SAR-bisPSMA)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-01